In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Seattle Genetics (SGEN), with a price target of $104.00. The company’s shares closed last Monday at $118.64, close to its 52-week high of $122.36.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.5% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Pacira Pharmaceuticals, and Emergent Biosolutions.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $122.91.
See today’s analyst top recommended stocks >>
The company has a one-year high of $122.36 and a one-year low of $62.90. Currently, Seattle Genetics has an average volume of 1.05M.
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SGEN in relation to earlier this year. Last month, Daniel G. Welch, a Director at SGEN bought 17,500 shares for a total of $223,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
